Radiation Oncology

Stage III NSCLC

Questions discussed in this category

Under what circumstances, if any, would you wait on initiating a TKI for metastatic recurrence of a Stage III NSCLC which occurred while on consolidative durvalumab to minimize pneumonitis risk?

One particular circumstance involved detecting a ROS1 fusion upon the metastatic recurrence. Is this pneumonitis risk seen with osimertinib alon...

2 Answers available

Do you consider NSCLC with multistation N2 involvement appropriate for treatment with neoadjuvant chemoimmunotherapy followed by surgery?

6 Answers available

Are there situations in which neoadjuvant chemoimmunotherapy + surgery would be preferred over chemoradiation + consolidative immunotherapy for stage III lung cancer?

1 Answer available

How do you manage pneumonitis in patients with Stage III NSCLC receiving durvalumab?

How do you prescribe a steroid taper? If it is grade 2, would you keep them on low dose prednisone while continuing? When do you feel comfortable re-c...

2 Answers available

How do you approach elderly patients with stage III NSCLC who have a reasonable performance status?

Do you recommend or make any modifications in the PACIFIC regimen for patients > 75 years of age?

1 Answer available

How do you monitor response for stage III NSCLC patients receiving consolidation immunotherapy?

CT or PET? If so, how often?

3 Answers available

How do you time re-staging studies and adjuvant durvalumab for stage III NSCLC treated with definitive cCRT?

Do you feel it is important to start durvalumab within 14 days of completing cCRT? What real life challenges do you face in doing so and wh...

1 Answer available

Do you recommend adjustment of lung dose constraints in the setting of stage III lung cancer treated with definitive concurrent chemoradiation followed by planned consolidation immunotherapy?

3 Answers available

Do you stop consolidative durvalumab after one year as per the PACIFIC trial or continue if the patient is otherwise tolerating well?

1 Answer available

Papers discussed in this category

The New England journal of medicine, 2018-12-13

Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC.

JAMA oncology, 2019-07-01

N Engl J Med, 2017 Nov 16

Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer.

Lancet (London, England), 2009-08-01

Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial.

The Lancet. Oncology, 2015-02

Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study.

J. Clin. Oncol., 2015 Nov 02

Phase III Study of Surgery Versus Definitive Concurrent Chemoradiotherapy Boost in Patients With Resectable Stage IIIA(N2) and Selected IIIB Non-Small-Cell Lung Cancer After Induction Chemotherapy and Concurrent Chemoradiotherapy (ESPATUE).

N Engl J Med, 2022 Apr 11

Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer.

Eur Respir J, 2005 Aug

Morbidity and mortality in the surgery arm of EORTC 08941 trial.

N Engl J Med, 2023 Jun 28

Perioperative Nivolumab and Chemotherapy in Stage III Non-Small-Cell Lung Cancer.

The New England journal of medicine, 2018 Apr 16

Neoadjuvant PD-1 Blockade in Resectable Lung Cancer.

The Lancet. Oncology, 2020 May 07

Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial.

Translational lung cancer research, 2019 Sep

Pathologic response after modern radiotherapy for non-small cell lung cancer.

European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery, 2009 Aug 21

Results of combined modality treatment in patients with non-small-cell lung cancer of the superior sulcus and the rationale for surgical resection.

Cancers, 2021 Sep 26

Management of Resectable Stage III-N2 Non-Small-Cell Lung Cancer (NSCLC) in the Age of Immunotherapy.

Clinical lung cancer, 2023 Jul 25

Effect of Surgical Treatment for N2-Positive c-stage III Non-Small Cell Lung Carcinoma in the "PACIFIC" Era.

ERJ open research, 2020 Feb 17

International guidelines on stage III N2 nonsmall cell lung cancer: surgery or radiotherapy?

Clinical Medicine Insights. Oncology, 2023 Feb 14

Evolving Therapeutic Scenario of Stage III Non-Small-Cell Lung Cancer.

J Thorac Oncol, 2018 Mar 06

Phase 1/2 Study of the Safety and Tolerability of Nivolumab Plus Crizotinib for the First-Line Treatment of Anaplastic Lymphoma Kinase Translocation - Positive Advanced Non-Small Cell Lung Cancer (CheckMate 370).

JTO clinical and research reports, 2022 Jun 25

Brief Report: Safety and Antitumor Activity of Alectinib Plus Atezolizumab From a Phase 1b Study in Advanced -Positive NSCLC.

Radiation Oncology

Stage III NSCLC

Questions discussed in this category

Papers discussed in this category

Related Topics in Radiation Oncology